- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04947137
Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This is a prospective, open-label, multicenter, single-dose study designed to develop a normative database of TUVjoint in HCs and to assess the feasibility of qualitative and quantitative SPECT/CT assessments in HCs and subjects with active RA.
This study is stratified into 2 arms. Arm 1 is comprised of HCs and Arm 2 is comprised of HCs and clinically diagnosed RA subjects on stable treatment.
Tipo di studio
Iscrizione (Anticipato)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Florida
-
Miami Lakes, Florida, Stati Uniti, 33014
- San Marcus Research Clinic
-
Palmetto Bay, Florida, Stati Uniti, 33157
- Innovation Medical Research Center
-
-
Ohio
-
Kettering, Ohio, Stati Uniti, 45429
- Kettering Medical Center
-
-
Oklahoma
-
Tulsa, Oklahoma, Stati Uniti, 74137
- Essential Medical Research
-
-
Pennsylvania
-
Duncansville, Pennsylvania, Stati Uniti, 16635
- Altoona Center For Clinical Research
-
-
Texas
-
San Antonio, Texas, Stati Uniti, 78215
- Sun Research Institute
-
Webster, Texas, Stati Uniti, 77598
- Tranquility Research
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
ALL SUBJECTS
- The subject has provided written informed consent with HIPAA (Health Information Portability and Accountability Act) authorization before the initiation of any study-related procedures.
The subject has agreed to not engage in any diet, lifestyle, or medication changes until study completion.
HEALTHY CONTROL SUBJECTS
- The subject is 30 years of age or greater at the time of consent.
- The subject is deemed to be clinically free of any inflammatory disease(s), autoimmune disease(s), or arthropathies and has not experienced joint pain for at least 28 days prior to the consent date.
- The subject is not currently on anti-inflammatory drugs (including non-steroidal anti-inflammatory drugs [NSAIDs]) and has not taken any anti-inflammatories for at least 28 days prior to the consent date.
- For all ongoing concomitant medications, the subject has maintained a stable dose for at least 28 days prior to the consent date.
CLINICALLY DIAGNOSED ACTIVE RA SUBJECTS
3. The subject is at least 18 years of age and was ≥ 18 years of age at the time of RA diagnosis.
4. The subject has moderate to severe RA as determined by the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Classification Criteria (score of ≥ 6/10).
5. The subject has a 28-joint disease activity score (DAS28) of ≥ 3.2 (includes the Erythrocyte Sedimentation Rate [ESR] test and Visual Analog Scale [VAS]).
6. Subjects receiving traditional DMARDs must have been on therapy for ≥ 90 days and at a stable dose for ≥ 30 days prior to the imaging visit (Day 0). 7. If the subject is receiving bDMARD or janus kinase (JAK) inhibitor therapy, they have been at a stable dose > 60 days prior to the imaging visit (Day 0). 8. If the subject is receiving NSAIDs or oral corticosteroids, the dose has been stable for ≥ 28 days prior to the imaging visit (Day 0). The corticosteroid dose must be ≤ 10 mg/day of prednisone or an equivalent steroid dose.
Exclusion Criteria:
- The subject is pregnant or lactating.
- The subject size or weight is not compatible with imaging per the investigator.
- The subject is currently receiving radiation therapy or chemotherapy or has received radiation therapy or chemotherapy in the past six months.
- The subject has had a finger, hand, and/or wrist amputation or hand or wrist joint arthroplasty.
- The subject has renal insufficiency as demonstrated by a glomerular filtration rate of < 60 mL/min.
- The subject has hepatic insufficiency as demonstrated by ALT (alanine aminotransferase [SGPT]) or AST (aspartate aminotransferase [SGOT]) greater than 2 times the upper limit of normal.
- The subject has any severe, acute, or chronic medical conditions and/or psychiatric conditions and/or laboratory abnormalities that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration that would deem the subject inappropriate for study participation or compromise the safety of the subject or the quality of the data.
- The subject has any unstable medical illnesses, including hepatic, renal, gastroenterologic, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease.
- The subject has a known allergy to or has had an adverse reaction to dextran exposure.
- The subject has received an investigational product within 30 days prior to Tc 99m tilmanocept administration (Day 0).
- The subject has received intra-articular corticosteroid injections ≤ 8 weeks prior to Tc 99m tilmanocept administration (Day 0).
- The subject has received any radiopharmaceutical within 7 days or 10 half-lives prior to Tc 99m tilmanocept administration (Day 0).
- Healthy Controls only: The subject has a positive rheumatoid factor and an elevated ESR or CRP.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Diagnostico
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Subjects Free of Inflammatory Disease
The first arm will be comprised of HCs who are deemed to be clinically free of inflammatory diseases, arthropathies, and/or arthroplasties and clinically free of joint pain for at least 28 days prior to the consent date.
|
Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
Altri nomi:
|
Sperimentale: Healthy Controls and RA Subjects on Stable Therapy
The second arm is comprised of [1] disease-free HCs and [2] clinically diagnosed RA subjects on stable treatment.
|
Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Normal Limits of TUVjoint in Healthy Subjects
Lasso di tempo: Up to 39 days
|
The normal limits of TUVjoint (on a per joint basis) in HC subjects, which are defined as the 5 and 95 percentiles of TUVjoint of bilateral joints (i.e., bilateral wrists, metacarpophalangeal joint [MCPs], proximal interphalangeal [PIPs]).
|
Up to 39 days
|
Qualitative Evaluation of SPECT/CT for Tilmanocept Localization
Lasso di tempo: Up to 39 days
|
Presence/absence of tilmanocept localization in the hands and wrists will be summarized with frequency counts and percentages by reader and joint.
|
Up to 39 days
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Normal Distribution of TUVjoint
Lasso di tempo: Up to 39 days
|
Applicability of the Normal (Gaussian) distribution to TUVjoint data as assessed by normal quantile plots provided per joint and reader and p-value for the Shapiro-Wilk test of Normality.
|
Up to 39 days
|
Quantitative Evaluation of SPECT/CT
Lasso di tempo: Up to 39 days
|
Determination of joint-specific standardized uptake value (SUV) from SPECT/CT imaging within synovial spaces of the bilateral hands and wrists in HCs and RA subjects.
|
Up to 39 days
|
Planar and SPECT/CT Comparison
Lasso di tempo: Up to 39 days
|
Assessment of the predictive value of planar scans for SPECT/CT scans.
|
Up to 39 days
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Michael Blue, MD, Navidea Biopharmaceuticals
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- NAV3-35
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Tc99m tilmanocept
-
Navidea BiopharmaceuticalsAttivo, non reclutante
-
Cardinal Health 414, LLCTerminatoNeoplasie cervicali uterineStati Uniti
-
Navidea BiopharmaceuticalsNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletatoInfezioni da HIV | Sarcoma di KaposiStati Uniti
-
Cardinal Health 414, LLCCompletato
-
Navidea BiopharmaceuticalsCompletatoSteatoepatite non alcolica | NASH - Steatoepatite non alcolicaStati Uniti
-
UMC UtrechtReclutamento
-
Navidea BiopharmaceuticalsRitirato
-
University Hospital, GhentNorgineRitiratoCancro al seno | Linfonodo sentinellaBelgio
-
Navidea BiopharmaceuticalsCompletato
-
Washington University School of MedicineLloyd J. Old STAR ProgramTerminatoNeoplasie del sistema nervoso centrale | Tumore del sistema nervoso centraleStati Uniti